Type 2 diabetes mellitus (T2DM), previously referred to as “noninsulin-dependent diabetes” or “adult-onset diabetes,” accounts for 90–95% of all diabetes. This form encompasses individuals who have relative insulin deficiency and have peripheral insulin resistance. At least initially, and often throughout their lifetime, these individuals may not need exogenous insulin treatment to survive. The risk factors of T2DM include increased age, obesity, lack of physical activity, hypertension, dyslipidemia, certain racial or ethnic subgroups (African American, American Indian, Hispanic/Latino, and Asian American), and prior gestational diabetes mellitus.

The treatment goal for T2DM is to reach the glycemic target and to prevent cardiovascular (CV) diseases and microvascular complications. Treatment regimens of T2DM include lifestyle modification and pharmacological treatment. First-line therapy of T2DM is metformin and comprehensive lifestyle changes, including weight management and physical activity.

There are multiple classes of medications indicated for T2DM, and a summary is provided in table 1. Subsequent newsletter articles are planned to discuss the classes in further detail. Other FDA-approved agents for T2DM include meglitinides (nateglinide and repaglinide), alpha-glucosidase inhibitor acarbose (Precose®, and generics) and miglitol (Glyset®, and generics), the immediate-release formulation of the ergot-derived dopamine agonist bromocriptine mesylate (Cycloset®), the bile acid sequestrant colesevelam (Welchol®, and generics), and the subcutaneously injected amylin mimetic pramlintide (Symlin®). None of these agents are recommended as monotherapy and they are minimally effective at reducing A1C (~0.5% reduction).

Pharmacological Treatment

2020 American Diabetes Association (ADA) Guidelines recommendations
1. Metformin should be started when T2DM is diagnosed and continued as long as it is tolerated and not contraindicated.
2. Early combination therapy can be considered in some patients presenting with A1C levels 1.5–2.0% above target.
3. The early introduction of insulin should be considered if there is evidence of ongoing catabolism (weight loss), if symptoms of hyperglycemia are present, or with very high A1C levels (>10%) or blood glucose levels (300 mg/dL).
4. Among patients with T2DM who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high risk, established kidney disease, or heart failure, a sodium–glucose cotransporter 2 (SGLT-2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with demonstrated CV disease and/or kidney disease benefits (Table 2) is recommended as part of the glucose-lowering regimen independent of A1C and in consideration of patient-specific factors.
5. In patients with T2DM who need greater glucose lowering than can be obtained with oral agents, GLP-1 receptor agonists are preferred to insulin when possible.
2020 American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) Guidelines recommendations 4

1. Independent of glycemic control, for patients with established ASCVD or high risk, chronic kidney disease, or heart failure with reduced ejection fraction (HFrEF), long acting GLP-1 receptor agonists or SGLT-2 inhibitors with proven efficacy (Table 2) are recommended.

2. For patients with recent-onset T2DM or mild hyperglycemia (A1C <7.5%), lifestyle therapy plus antihyperglycemic monotherapy (preferably with metformin) is recommended.

3. Patients who present with an A1C >7.5% (whether newly diagnosed or not) and who are not already taking any anti-hyperglycemic agents should be started initially on metformin plus another agent in addition to lifestyle therapy.

4. Patients with A1C >9.0% who are symptomatic (presenting with polyuria, polydipsia, or polyphagia) would likely derive the greatest benefit from the addition of insulin, but if presenting without significant symptoms, these patients may initiate therapy with maximum doses of two or three other medications.

Conclusion:
First-line therapy of T2DM is metformin plus lifestyle therapy. Metformin is the preferred initial glucose-lowering medication for most people with T2DM and should be continued as long as it is tolerated and not contraindicated. Since there are now multiple large randomized controlled trials reporting statistically significant reductions in cardiovascular events, heart failure events, or renal events in patients with T2DM treated with SGLT-2 inhibitors or GLP-1 receptor agonists, these two classes of medications with proven efficacy are recommended to add to treatment regimens for patients with T2DM and indicated diseases.

Table 1: Pharmacological treatment for T2DM 3,4,6,7,8

<table>
<thead>
<tr>
<th>Medication Classes</th>
<th>Mechanism of action</th>
<th>Common adverse effects</th>
<th>Severe adverse effects</th>
<th>Black box warning/contraindication</th>
<th>Medications in class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanide</td>
<td>Decreases hepatic glucose production; Increases secretion of GLP-1; Reduces intestinal absorption of glucose; Increases peripheral glucose uptake</td>
<td>Gastrointestinal (GI) side effects (nausea, vomiting, diarrhea); Injection site reactions</td>
<td>Lactic acidosis (very high circulating level)</td>
<td>Lactic acidosis Cl; eGFR &lt;90 ml/minute/1.73 m²</td>
<td>Metformin/ER</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Potentiate glucose-dependent secretion of insulin; Suppress glucagon secretion; Slow gastric emptying; Promote satiety</td>
<td>GI side effects (nausea, vomiting, diarrhea); Injection site reactions</td>
<td>Acute pancreatitis</td>
<td>Thyroid C-cell tumors Cl; eGFR &lt;90 ml/minute/1.73 m² (exenatide) and eGFR &lt;15 ml/minute/1.73 m² (lixisenatide); Severe gastrointestinal disease (exenatide, lixisenatide); Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (lixisenatide, dulaglutide, exenatide)</td>
<td>Dulaglutide (Trulicity®); Exenatide (Byetta®, Bydureon®); Linagliptide (Victoza®); Lixisenatide (Adlyxin®); Semaglutide (Ozempic®, Rybelsus®)</td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Decrease renal glucose reabsorption; Increase urinary glucose excretion</td>
<td>Genitourinary infections; Slightly increased LDL-C levels; Volume depletion (may lead to initial renal impairment, hypotension, syncope, and falls)</td>
<td>Diabetic ketoacidosis (DKA) (rare in T2DM); Acute kidney injury; Fournier’s gangrene (rare); Bladder cancer (dapagliflozin); Bone fractures (canagliflozin)</td>
<td>Risk of amputation (canagliflozin) Cl; eGFR &lt;90 ml/minute/1.73 m²</td>
<td>Canagliflozin (Invokana®); Dapagliflozin (Farxiga®); Empagliflozin (Jardiance®); Ertugliflozin (Steglatro®)</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>Potentiate glucose-dependent secretion of insulin; Suppress glucagon secretion</td>
<td>Joint pain</td>
<td>Acute pancreatitis; Increased risk of heart failure (saxagliptin and alogliptin)</td>
<td>Angiography (Ressa®) Linagliptin (Trajenta®) Saxagliptin (Onglyza®) Sitagliptin (Januvia®)</td>
<td>Alogliptin (Nesina®) Linagliptin (Trajenta®) Saxagliptin (Onglyza®) Sitagliptin (Januvia®)</td>
</tr>
<tr>
<td>TZDs</td>
<td>Increase the insulin sensitivity of adipose tissue, skeletal muscle, and the liver; Reduce hepatic glucose production</td>
<td>Weight gain, edema; Anemia; Increased fracture risk; Increased LDL-C level (rosiglitazone)</td>
<td>Congestive heart failure; Bladder cancer (pioglitazone)</td>
<td>Congestive heart failure Cl; Heart failure or fluid overload; History of fracture or at high risk for fracture; Active liver disease; Active or history of bladder cancer; Pregnancy</td>
<td>Pioglitazone (Actos®) Rosiglitazone (Avandia®)</td>
</tr>
<tr>
<td>Sulfonylureas (2nd generation)</td>
<td>Interact with adenosine triphosphate (ATP)-sensitive potassium channels in the pancreatic beta-cell membrane to increase secretion of insulin</td>
<td>Weight gain; Hypoglycemia</td>
<td>Sulfonylurea (&quot;sufla&quot;) allergy</td>
<td>Gliclazide/ER Glipizide/ER</td>
<td>Gliclazide/ER Glipizide/ER</td>
</tr>
<tr>
<td>Insulin</td>
<td>Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats.</td>
<td>Weight gain; Hypoglycemia Injection site reactions</td>
<td>Various products</td>
<td>Various products</td>
<td>Various products</td>
</tr>
</tbody>
</table>

Bold: indicates Medicad preferred medications; • indicates Medicad preferred medications with clinical criteria; • indicates preferred by guidelines for atherosclerotic cardiovascular diseases (ASCVD); •• indicates preferred by guidelines for heart failure; •• indicates preferred by guidelines for kidney disease.
Table 2: Characteristics of medication classes for T2DM 1,3

<table>
<thead>
<tr>
<th>Medication Classes</th>
<th>Route</th>
<th>Efficacy (A1C reduction)</th>
<th>ASCVD benefits</th>
<th>HF benefits</th>
<th>Nephropathy benefits</th>
<th>Hypoglycemia benefits</th>
<th>Weight change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanide</td>
<td>Oral</td>
<td>1-1.5%</td>
<td>Potential benefits: metformin</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Low risk</td>
<td>Neutral</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Subcutaneous, oral (Rybelsus®)</td>
<td>1-1.5%</td>
<td>Benefits: liraglutide* semaglutide dulaglutide</td>
<td>Benefits: liraglutide*</td>
<td>Benefits: liraglutide*</td>
<td>Low risk</td>
<td>Loss</td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Oral</td>
<td>0.5-1%</td>
<td>Benefits: empagliflozin* canagliflozin</td>
<td>Benefits: dapagliflozin* empagliflozin*</td>
<td>Benefits: canagliflozin</td>
<td>Low risk</td>
<td>Loss</td>
</tr>
<tr>
<td>DPP-4 Inhibitors</td>
<td>Oral</td>
<td>0.5-1%</td>
<td>Neutral</td>
<td>Potential risk: saxagliptin</td>
<td>Neutral</td>
<td>Low risk</td>
<td>Neutral</td>
</tr>
<tr>
<td>TZDs</td>
<td>Oral</td>
<td>1-1.5%</td>
<td>Potential benefits: pioglitazone</td>
<td>Increased risk</td>
<td>Neutral</td>
<td>Low risk</td>
<td>Gain</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>Oral</td>
<td>1-1.5%</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>High risk</td>
<td>Gain</td>
</tr>
<tr>
<td>Insulin</td>
<td>Subcutaneous, inhale (Afrezza®)</td>
<td>Most potent</td>
<td>Neutral</td>
<td>Neutral</td>
<td>Neutral</td>
<td>High risk</td>
<td>Gain</td>
</tr>
</tbody>
</table>

References:

The P&T Committee met for its quarterly business meeting on February 11, 2021

Highlights of this meeting include:

- Dr. Joe Horam will be leaving the Committee after twelve years of service due to term limits defined in the bylaws. His input has been invaluable and he will be greatly missed. A pediatrician will be sought to fill his open position.

- System changes have been completed to allow pharmacies to bill for administration of the COVID-19 vaccination. The updates will be active February 16, 2021 and pharmacies may back bill for vaccinations administered after January 1, 2021.

- Oxlumo will be limited to indication.

- Montelukast (Singulair) dosages will be limited to the labeled maximums. These are 4 mg for children 0 – 5 years old, 5 mg for 6 – 14 years and 10 mg for patients 15 years and older.

The proposed prior authorization criteria are open for public comment. Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board
Dept. 3375, 1000 E. University Avenue
Laramie, WY 82071.

Comments should be received prior to April 15, 2021.

The next P&T Committee meeting will be held May 13, 2021 in Cheyenne. An agenda will be posted approximately two weeks prior to the meeting.
March 2021

In This Issue

Type 2 Diabetes Mellitus and Pharmacological Therapies
P&T Committee Meeting Update

Please contact WY-DUR at 307-766-6750 to have your name added or removed from our mailing list, or if you need to update your address. The WY-DUR newsletter is also available on-line at www.uwyo.edu/DUR/newsletters.